<DOC>
	<DOCNO>NCT00836160</DOCNO>
	<brief_summary>This observational prospective study investigate daily practice . The prescription anti-cancer medicine separate decision include patient study . In addition , assignment patient particular therapy therapeutic strategy decide advance study protocol , fall within current practice . The patient fulfil eligible criterion enrol start receive second-line EGFR-TKI therapy . The frequency tumor response evaluation RECIST criterion follow investigator 's discretion daily practice .</brief_summary>
	<brief_title>Comparing Efficacy Between Anti-microtubule Non-anti-microtubule 3th Therapy After 2nd Line EGFR-TKI Therapy</brief_title>
	<detailed_description />
	<criteria>At least one measurable lesion accord RECIST criterion Histologically cytologically confirm NSCLC adeno histology Locally progress metastasize firstline chemotherapy . The image evidence disease progression either chest X ray , CT MRI assessment measurable lesion . If measurable lesion available , evaluable lesion acce</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>EGFR-TKI therapy</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Efficacy</keyword>
</DOC>